Articles tagged with Cancer Medication
Scientists have developed novel conjugates made from antibodies and a kinesin spindle protein inhibitor, showing high effectiveness in vitro and tumor models. The linker between components allows for tuning the activity of the cytostatic drug, reducing side effects in cancer treatment.
Scientists have discovered how the Seneca Valley Virus interacts with tumor receptors, allowing it to selectively target cancer cells while sparing healthy tissues. The study provides detailed images of the virus and its receptor, enabling researchers to design improved cancer therapies.
Biophysicists at Ruhr-University Bochum developed a Raman microscopy method to detect cancer drug resistance in tumour cells. The new approach shows effectiveness in non-mutated cells but remains ineffective in mutated cells, similar to clinical observations.
Researchers discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes silenced by cancer. This leads to restored tumor suppressor gene expression and enhanced anti-cancer immunity. The new epigenetic drug strategy shows broad effectiveness against cancer in both in vitro and in vivo studies.
Researchers at Harvard University have discovered that tetracycline antibiotics target human cytosolic ribosomes, leading to potential breakthroughs in treating cancer and pathological inflammation. The study provides a crucial foundation for further drug discovery and treatment development.
A phase III clinical trial found that palbociclib improves overall survival in women with hormone receptor-positive metastatic breast cancer. The drug, used in combination with standard treatment, led to a clinically meaningful improvement in median overall survival, even in patients who showed sensitivity to prior hormone therapy.
Researchers have created a comprehensive summary of human cancer genes, known as the Cancer Gene Census. The resource catalogues over 700 genes involved in cancer and describes their functions across different types. This knowledge will help scientists find drug targets and design treatments tailored to individual cancers.
A study found that angiotensin converting enzyme inhibitor (ACEI) drugs increase the risk of lung cancer by 14% compared to angiotensin receptor blockers (ARBs). The risk is highest among patients using ACEIs for over five years, particularly those who use them for more than 10 years.
The partnership aims to find new cancer drugs and attract diverse researchers to focus on cancers with increased risk of incidence and mortality among African-Americans, Hispanics, and Native Americans. The program will also enhance current researchers' awareness and knowledge of cancer health disparities.
Researchers developed a new combination treatment that flips the switch on melanoma cells by targeting Bcl-2, MCL-1, and DRP-1 proteins. The approach killed melanoma cells and cancer stem cells in laboratory tests, offering an alternative option for patients who don't respond to current treatments.
A new study shows that targeting the specific genomic mutation PIK3CA in hormone receptor-positive HER2-negative advanced breast cancer patients significantly improves progression-free survival. The study found that nearly twice as long PFS was observed in patients with PIK3CA mutations treated with alpelisib compared to the placebo gr...
A new immunotherapy combination shows durable clinical benefits in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer, with 60% objective response rate and 84% of patients experiencing tumour shrinkage. The treatment is also well-tolerated, with manageable side effects.
A new approach to treating advanced anal cancer is safer and more effective than current treatment, according to a randomised clinical trial. The study found that a chemotherapy combination of Carboplatin and Paclitaxel performed better in terms of survival rates and safety compared to Cisplatin and 5-fluorouracil.
Oncologists require more education on the use of biosimilars, which could increase patient access to innovative therapies due to economic constraints. ESMO supports their use as cheaper alternatives to reference biologics, promoting sustainable and widely accessible cancer care.
The combination of avelumab and axitinib improved progression-free survival (PFS) by 6.6 months in previously untreated patients with advanced renal cell carcinoma, with confirmed objective response rates of 55.2% and 25.5%. The study's findings support the potential of this new treatment approach for patients with advanced RCC.
A Phase III clinical trial shows that combining immunotherapy with chemotherapy improves progression-free and overall survival for patients with triple-negative breast cancer. The study's results establish a new standard of care in PD-L1+ patients and provide hope for those diagnosed with this aggressive form of breast cancer.
A study found huge variations in time between European countries to reach health technology assessment decisions on new cancer drugs, with some taking over a year. The average decision time was longer than one year in England and Scotland compared to Germany and France.
The ESMO 2018 Congress emphasizes the importance of integrating scientific advances into sustainable treatments, ensuring optimal cancer care reaches those who need it. Research highlights variations in European countries' approval times for new cancer drugs, emphasizing the need for timely reimbursement decisions.
Researchers discovered Src activates mTORC1 through amino acid signals, found to be hyperactive in cancer. Src's malfunction leads to continuous signaling for cell growth and cancer progression.
Children with inflammatory bowel disease have a higher mortality rate compared to peers without the condition, particularly if diagnosed before age 18. Careful monitoring is crucial for individuals diagnosed in childhood, especially those with ulcerative colitis and primary sclerosing cholangitis.
The Case Comprehensive Cancer Center has received a $3 million NIH grant to investigate racial disparities in colorectal and breast cancer. The research program aims to identify genetic biomarkers for cancer specific to high-risk populations and promote medical and social policies that benefit communities.
Scientists discover that healthy oesophagus tissue contains hundreds to thousands of mutations per cell by middle age, with only a dozen genes driving competition. The study reevaluates the role of some cancer genes in light of normal tissue sequencing, raising new questions about ageing and disease progression.
Researchers at City of Hope have developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses, eliminating difficult-to-treat prostate cancer in experimental models. The novel two-step strategy relies on two opposite actions of the same 'hot and cold' molecule to remove obstacles to treating me...
Researchers have released a massive dataset detailing molecular makeup of tumor cells from over 500 AML patients, enabling rapid advancement in clinical trials. The dataset includes how individual patients' cells responded to various drugs, providing insights into targeted therapies for specific subsets of AML cells.
Researchers at Ohio State University Wexner Medical Center found that papaverine inhibits mitochondrial respiration and sensitizes model tumors to radiation. The study suggests that modifying the papaverine molecule could lead to a new class of radiosensitizing drugs with fewer side effects.
A University of Cincinnati researcher is working on a new light therapy that uses ultraviolet light to activate light-sensitive drugs, selectively targeting cancer cells while sparing healthy stem cells. This approach has the potential to be more effective and safer than current treatments.
A study in Germany shows that cancer patients face substantial financial impacts, including income loss and material hardship, with adverse psychological effects. The survey of 247 patients revealed that 80.6% faced higher out-of-pocket costs and 37.2% experienced significant income loss.
Researchers at USC and the Los Angeles Cancer Surveillance Program found that 15- to 39-year-olds have the best survival rate among any age group for many years. The analysis adjusted for Kaposi's sarcoma and lymphomas, which were linked to the HIV/AIDS epidemic in the US.
A clinical trial at UC San Diego Health is testing personalized vaccines that use a patient's unique cancer mutations to stimulate an immune response. The vaccine, combined with an FDA-approved checkpoint inhibitor, aims to unleash the full potential of T cells activated by the vaccine.
Researchers have developed a laboratory model that accurately evaluates MCL-1 inhibitors, enabling the identification of right patients for these drugs. The model predicts how cancer patients will respond to the drug in the clinic, allowing for effective treatment and potential breakthroughs in cancer therapy.
Two new clinical trials are underway at Cummings Veterinary Medical Center at Tufts University to study deadly cancers in dogs. These studies focus on osteosarcoma and solid tumors, and may provide valuable information for human cancer treatments.
Researchers have revealed the structure of immune protein IgM, showing it to be an incomplete hexagon. This discovery has significant implications for developing effective medicines for various diseases, including cancer and neurological disorders. The structural connection between IgM and AIM proteins suggests that drugs targeting AIM...
Three leading researchers, Ian Smith, Ann Partridge, and Zena Werb, receive top honors for their groundbreaking work on breast cancer treatment and research. Their contributions have propelled advances in breast cancer science and medicine, saving countless lives from the disease.
A study of over 6,000 patients with advanced cancer treated in community settings shows that nearly a quarter received targeted treatment based on DNA mutations. This achievement marks a significant shift towards precision medicine, allowing more patients to benefit from innovative therapies.
A commonly-used anti-psychotic drug has shown promise in treating aggressive triple negative breast cancer by inhibiting the growth and spread of cancer cells. The study found that up to 90% of cancer cells died following treatment with Pimozide, reducing tumour size and metastases.
Researchers at Case Western Reserve University have identified a previously uncharacterized structure within the human estrogen receptor that could serve as a valuable new drug target. By disrupting this interface, drugs may be able to inhibit receptor function and prevent metastasis.
A recent study found that palbociclib, a breast cancer drug, can effectively treat acute myeloid leukaemia (AML) with reduced toxicity compared to current chemotherapy. This breakthrough could lead to improved survival rates for patients with the serious condition.
A study published in Nature identified a tumor cell population responsible for resistance to therapy and tumor relapse in basal cell carcinoma. The researchers found that vismodegib promotes the differentiation of tumor cells, leading to their elimination, but also reveals a dormant population of tumor cells with active Wnt signaling.
Patients with AFib and a history of cancer are more likely to experience suboptimal antithrombotic care, leading to increased risk of stroke. Cardiology providers play a crucial role in improving outcomes for these patients, according to a study published in the Journal of the American College of Cardiology.
A new mouse study builds on human findings that link chemotherapy and the APOE4 gene variant to cognitive problems. The research, published in Neurotoxicity Research, reveals that APOE4 works with doxorubicin to cause significant brain changes and impair learning.
Sanjay Awasthi's research blocks stress-responsive protein Rlip to defeat deleterious effects of p53 loss, a common genetic defect in breast cancers. This discovery could lead to effective new medications for cancer, diabetes, and other health issues.
Scientists have found an old antibiotic that selectively kills cells producing high levels of ALDH1 in melanoma tumors. The therapy shows promise for complementing existing treatments and may offer a new approach to targeting drug resistance.
Researchers identified over 500 DNA sites requiring ATR enzyme to prevent breakage during replication. The findings suggest ATR inhibitors may enhance treatment efficacy for various cancers by targeting repetitive DNA sequences.
Researchers at The Wistar Institute developed synthetic DNA-encoded monoclonal antibodies targeting CTLA-4, achieving antitumor activity comparable to traditional monoclonals. The approach stimulates robust CD8+ T-cell infiltration and tumor clearance in mouse models.
Researchers have discovered a potential treatment for prostate cancer using riluzole, a drug approved for ALS treatment. The study found that riluzole promotes the degradation of androgen receptors, which drives prostate cancer growth.
Researchers at Stevens Institute of Technology have designed a novel molecule that uses a unique mechanism to halt or destroy breast cancer tumors. The molecule, developed by Abhishek Sharma, could potentially add to the arsenal of drugs targeting estrogen receptors in breast cancer therapy.
A researcher at UCF College of Medicine has discovered a way to make immunotherapy viable for thousands by using the body's own natural killer (NK) cells in a new way. Activated NK cells can change the cellular makeup of tumors, allowing the immune system to attack cancer more effectively.
The Cell Model Passports hub provides a central platform for accessing high-quality cancer cell models and genomic data. This will streamline the process of finding relevant models for research, enabling scientists to accelerate cancer research and develop new treatments.
Researchers found that deep space bombardment can significantly damage gastrointestinal tissue, leading to long-term functional alterations and high risk of tumor development. The study's findings raise concerns about the health of astronauts on long voyages, such as Mars.
The new system can produce different proteins in a fully automated, hands-free manner and is of comparable quality to commercially available versions. It enables flexible switching between products as they are needed, making it useful for producing rare disease treatments.
A McMaster University-led review of 52 articles found no significant association between progression-free survival and health-related quality of life in cancer patients. The study suggests that clinical trials should measure health-related quality of life directly to ensure patients are receiving effective treatments.
A new study from George Washington University Cancer Center found that nanoparticle-encapsulated doxorubicin is promising in treating triple-negative breast cancer. The smallest nanoparticles with slowest release of medication showed increased cell kill in resistant cancer cells, offering potential strategies to overcome drug resistance.
Moffitt researchers used a new technique to identify a previously unknown mechanism of midostaurin in lung cancer. Combining functional proteomics with deep network analysis led to the discovery of TBK1, PDPK1, and AURKA as protein targets for midostaurin, resulting in a more effective combination therapy.
Loyola will produce a more purified CAR-T cell product potentially reducing toxicities and costs. The Leukemia Research Foundation is supporting the research with a $250,000 grant.
Researchers at UCI will develop a new class of cancer-killing immunotherapeutics targeting abnormal glycans, which are nearly universal in cancer but limited in normal tissue. The goal is to broaden the types of cancers sensitive to immunotherapy and treat highly diverse types of cancer.
A Phase III clinical trial is enrolling men with metastatic Stage 4 prostate cancer to compare standard systemic therapy with or without surgery or radiation therapy. The goal is to delay disease progression and improve survival.
Researchers at the University of Liverpool discovered a lung cancer drug that can degrade 'zombie' proteins linked to leukemia. The study highlights the potential for repurposing drugs to target cancer therapies, particularly in acute myeloid leukaemia and acute lymphoblastic leukaemia.
A new drug called Metavert has shown promising results in blocking pancreatic cancer growth in laboratory mice. The study also found that Metavert may prevent patients from developing resistance to currently used chemotherapies.
Researchers developed a theranostic complex that targets tumor cells with two toxic modules, showing high therapeutic efficacy and imaging contrast. The complex uses yttrium-90-doped upconversion nanoparticles and targeted toxin to inhibit tumor growth and reduce drug resistance.
Scientists at Boston Children's Hospital have identified a potential new treatment for adenoid cystic carcinoma by targeting the MYB gene in zebrafish. The study found that retinoic acid derivatives effectively shut off the MYB gene, slowing tumor growth and validating its efficacy in human cells.